- Home
- FA vs HCM Comparison
FA vs HCM Comparison
Compare FA & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FA
- HCM
- Stock Information
- Founded
- FA 2003
- HCM 2000
- Country
- FA United States
- HCM Hong Kong
- Employees
- FA N/A
- HCM N/A
- Industry
- FA Business Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- FA Consumer Discretionary
- HCM Health Care
- Exchange
- FA Nasdaq
- HCM Nasdaq
- Market Cap
- FA 3.0B
- HCM 2.5B
- IPO Year
- FA 2021
- HCM N/A
- Fundamental
- Price
- FA $16.79
- HCM $16.40
- Analyst Decision
- FA Hold
- HCM Strong Buy
- Analyst Count
- FA 6
- HCM 1
- Target Price
- FA $20.75
- HCM $28.00
- AVG Volume (30 Days)
- FA 897.7K
- HCM 45.7K
- Earning Date
- FA 08-07-2025
- HCM 08-07-2025
- Dividend Yield
- FA N/A
- HCM N/A
- EPS Growth
- FA N/A
- HCM N/A
- EPS
- FA N/A
- HCM 0.53
- Revenue
- FA $1,251,464,000.00
- HCM $602,197,000.00
- Revenue This Year
- FA $82.86
- HCM $15.00
- Revenue Next Year
- FA $6.36
- HCM $19.91
- P/E Ratio
- FA N/A
- HCM $5.83
- Revenue Growth
- FA 65.34
- HCM N/A
- 52 Week Low
- FA $12.32
- HCM $11.51
- 52 Week High
- FA $20.79
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- FA 49.34
- HCM 48.75
- Support Level
- FA $15.61
- HCM $15.80
- Resistance Level
- FA $17.29
- HCM $16.17
- Average True Range (ATR)
- FA 0.79
- HCM 0.49
- MACD
- FA -0.03
- HCM -0.23
- Stochastic Oscillator
- FA 49.46
- HCM 37.14
About FA First Advantage Corporation
First Advantage Corp is a provider of employment background screening and verification solutions. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment, which performs various background checks and compliance services across all phases of the workforce lifecycle, from pre-onboarding services to post-onboarding and ongoing monitoring services, covering employees, contractors, contingent workers, tenants, and drivers. The company delivers solutions across multiple industry verticals in the United States, Canada, and Latin America. Geographically, it derives key revenue from the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.